Healthcare, Pharma & Life Sciences

Lakewood-Amedex CEO to Present Bisphosphocin Data at Three Investor Events

Image
Lakewood-Amedex CEO to Present Bisphosphocin Data at Three Investor Events

Sarasota, Fla. – October 01, 2026 -- Lakewood-Amedex Biotherapeutics, Inc. (NASDAQ: LABT) will send CEO Kelvin Cooper, Ph.D., to three separate industry conferences this month, placing the clinical-stage antimicrobial developer in front of both investors and infectious-disease specialists within an eight-day window.

CEO to address investor audiences at two New York events in mid-October

Cooper is scheduled to attend the Maxim Growth Summit on October 14, 2026, in New York City, followed by a presentation at the ThinkEquity Conference on October 15, 2026, also in New York City. Both appearances target biotechnology investors evaluating the company's pipeline.

Guardian System Cuts ECMO Pressure Injuries 36.2% in New Study

Image
Guardian System Cuts ECMO Pressure Injuries 36.2% in New Study

Palo Alto, Calif. – October 01, 2026 -- TurnCare, Inc. reported a 36.2% reduction in total hospital-acquired pressure injuries (HAPIs) among ECMO patients following implementation of its GuardianTM System, according to new clinical data presented at the 37th Annual Extracorporeal Life Support Organization (ELSO) 2026 Conference in Nashville, Tennessee.

Single-center study tracks outcomes across 2,707 ECMO days

The retrospective pre- and post-cohort analysis, conducted at M Health Fairview University of Minnesota Medical Center, compared a baseline group of 317 ECMO patients (327 runs, 2,112 ECMO days) against a Guardian-treated cohort of 92 patients (97 runs, 595 ECMO days). Chris Linke, MHI, RN, CSSMBB, presented the findings.

HoneyNaps Gains CRO Status, Expands AI Sleep Data Services for Pharma

Image
HoneyNaps Gains CRO Status, Expands AI Sleep Data Services for Pharma

Boston – October 01, 2026 -- HoneyNaps, an AI-based sleep health technology company, has completed registration as a clinical research organization (CRO) with South Korea's National Enterprise for Clinical Trials (KoNECT), broadening its role in pharmaceutical and medical device trials worldwide.

HoneyNaps secures CRO registration with KoNECT, expanding multicenter trial capacity

The company has supported clinical trials involving more than 10,000 participants and can now operate multicenter, multidisciplinary studies under its new CRO status. The registration formalizes HoneyNaps' position as a provider of standardized sleep data analysis for pharmaceutical companies, medical device developers, and research organizations.

Lutris Pharma's LUT014 Gel Hits 71.8% Success Rate in Phase 2 Rash Trial

Image
Lutris Pharma's LUT014 Gel Hits 71.8% Success Rate in Phase 2 Rash Trial

Tel Aviv, Israel – October 01, 2026 -- Lutris Pharma reported that its topical B-Raf inhibitor LUT014 achieved Treatment Success in 71.8% of patients with EGFR inhibitor-induced acneiform rash, compared with 38.5% on placebo (p=0.003), in updated Phase 2 data presented at the 35th EADV Congress in Vienna.

LUT014 0.1% gel cuts clinician-assessed rash severity and patient symptom burden

Among the composite endpoint's components, 56.4% of patients on LUT014 0.1% achieved at least a one-grade improvement on the CTCAE v5.0 acneiform rash scale versus 15.4% on placebo (p=0.0002). Using the FACT-EGFRI-18 patient-reported symptom score, 53.8% of treated patients reported at least a five-point improvement versus 28.2% on placebo (p=0.021).

Brogidirsen Shows 5-Year Motor Function Benefit in DMD Trial

Image
Brogidirsen Shows 5-Year Motor Function Benefit in DMD Trial

Paramus, N.J. – October 01, 2026 -- NS Pharma, Inc. reported 5-year efficacy and safety data showing its investigational therapy brogidirsen maintained or improved motor function in Duchenne muscular dystrophy (DMD) patients amenable to exon 44 skipping, with zero treatment discontinuations across the study period.

Six-participant trial records no serious adverse events over five years

The data, presented by Japan's National Center of Neurology and Psychiatry (NCNP) at the 31st annual International Congress of the World Muscle Society in Hiroshima, Japan, covered an open-label extension of an investigator-initiated clinical trial. All six participants received weekly intravenous dosing of brogidirsen (NS-089/NCNP-02), an antisense oligonucleotide co-discovered by Nippon Shinyaku and NCNP. After five years of administration, no serious or severe adverse events, anaphylaxis, or discontinuations tied to long-term dosing were recorded.

Nanoscope's MOGENRY Gains Priority Review in Japan for IRD Patients

Image
Nanoscope's MOGENRY Gains Priority Review in Japan for IRD Patients

Dallas – October 01, 2026 -- Japan's Pharmaceuticals and Medical Devices Agency (PMDA) has accepted and granted priority review to Nanoscope Therapeutics' New Drug Application for MOGENRY (sonpiretigene isteparvovec, MCO-010), an optogenetic gene therapy for inherited retinal dystrophies (IRDs). If approved by the Ministry of Health, Labour and Welfare, MOGENRY would become the first disease-agnostic treatment available to IRD patients in Japan, a condition caused by mutations across more than 250 genes that leads to progressive photoreceptor loss and blindness.

CHOP Names Joseph Mitchell CEO, Succeeding 11-Year Chief Madeline Bell

Image
CHOP Names Joseph Mitchell CEO, Succeeding 11-Year Chief Madeline Bell

Philadelphia – October 01, 2026 -- Children's Hospital of Philadelphia (CHOP) has officially installed Joseph Mitchell, MD, as President and Chief Executive Officer, succeeding Madeline Bell after her nearly four-decade tenure and 11 years as CEO.

Mitchell completes an 18-month transition after joining CHOP as President in April 2025

Mitchell spent the past year and a half working alongside CHOP leadership, clinicians, researchers and community partners ahead of taking full control of the nation's first children's hospital, an institution founded more than 170 years ago.

Baptist Health Care, PAM Health Revise JV to Add 100 Beds

Pensacola, Fla. – October 01, 2026 -- Baptist Health Care and PAM Health have restructured their joint venture, adding 40 acute care beds at Baptist Hospital and building a freestanding 60-bed inpatient rehabilitation hospital at Baptist Medical Park – Nine Mile, pushing Baptist Hospital's total bed count from 279 to 319.

Revised plan scraps original 40-bed rehab unit for larger freestanding facility

The updated agreement replaces a plan first announced in early 2025, which called for a 40-bed inpatient rehabilitation hospital housed within the Henderson Health Center on the Baptist Hospital campus. Under the new structure, PAM Health and Baptist Health Care will instead construct a standalone 60-bed rehabilitation hospital at the Nine Mile campus, freeing the Henderson Health Center space for conversion into a 40-bed acute care unit.

SciBase Secures SEK 57.5M as Rights Issue Fully Subscribed

Stockholm – October 01, 2026 -- SciBase Holding AB has closed its rights issue fully subscribed, raising approximately SEK 57.5 million before issue costs to fund continued commercialisation of its Nevisense melanoma-diagnostics platform in the United States.

Shareholders cover nearly three-quarters of the offering

The subscription period, which ran through 29 September 2026, saw 2,681,085 shares subscribed with the support of subscription rights, equal to roughly SEK 40.2 million, or 69.9 percent of the issue. An additional 133,116 shares were subscribed without subscription rights, adding SEK 2.0 million, or 3.5 percent. In total, 2,814,201 shares were subscribed with and without rights, covering approximately SEK 42.2 million, or 73.4 percent of the SEK 57.5 million target.